Traumatic Brain Injury – Pipeline Review, H1 2019

Source: https://www.researchbymarkets.com/report/traumatic-brain-injury-pipeline-review-h1-2019-268221.html

For queries regarding this report: https://www.researchbymarkets.com/sample-request/268221

Traumatic Brain Injury Therapeutic Products under Development, Key Players in Traumatic Brain Injury Therapeutics, Traumatic Brain Injury Pipeline Overview, Traumatic Brain Injury Pipeline, Traumatic Brain Injury Pipeline Assessment

Traumatic Brain Injury – Pipeline Review, H1 2019

Summary

Traumatic Brain Injury – Pipeline Review, H1 2019, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer’s disease and coordination problems.

Report Highlights

Traumatic Brain Injury – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 8, 77 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Alexion Pharmaceuticals Inc
ALSP Inc
AlzeCure Pharma AB
AMAG Pharmaceuticals Inc
Amarantus Bioscience Holdings Inc
Anagin Inc
Aptinyx Inc
Athersys Inc
Avanir Pharmaceuticals Inc
Biogen Inc
CalciMedica Inc
Cantex Pharmaceuticals Inc
CereSpir Inc
Cognosci Inc
Complement Pharma BV
Eisai Co Ltd
Epigen Biosciences Inc
Hemarina SA
Hoverink Biotechnologies Inc
International Stem Cell Corp
Ischemix Inc
JT Pharmaceuticals Inc
Levolta Pharmaceuticals Inc
Mapreg SAS
Neuralstem Inc
Neuren Pharmaceuticals Ltd
NeuroNascent Inc
NeuroVive Pharmaceutical AB
New World Laboratories Inc
NoNO Inc
NuvOx Pharma LLC
Nyrada Inc
Oxeia Biopharmaceuticals Inc
Peptron Inc
Prevacus Inc
ProThera Biologics Inc
QR Pharma Inc
Qrons Inc
Radikal Therapeutics Inc
RegeneRx Biopharmaceuticals Inc
Resolys Bio Inc
Rubicon Biotechnology Inc
Sage Therapeutics Inc
Silver Creek Pharmaceuticals Inc
STATegics Inc
Stemedica Cell Technologies Inc
SynZyme Technologies LLC
Tetra Discovery Partners LLC
Therapeutic Solutions International Inc
Therapix Biosciences Ltd
TikoMed AB
Tiziana Life Sciences Plc
vasopharm GmbH
VG Life Sciences Inc
Virogenomics BioDevelopment Inc

Contact Us:

ResearchByMarkets.com

Ritesh Tiwari, Director

enquiry@researchbymarkets.com

USA: +1-800-416-3124

https://www.researchbymarkets.com/aboutus

Follow us on Social Media:

Facebook: https://www.facebook.com/researchbymarkets/

LinkedIn: https://www.linkedin.com/company/researchbymarkets/

Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.